GlassScriptPhysician profile
Keith A Reich
NPI 1902863285
$193,112.08
in general payments reported to CMS, 2019-2025
15 companies · $48K in 2025
The $48K reported for 2025 was more than what 96% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $600 · 2020: $8,701 · 2021: $10K · 2022: $28K · 2023: $60K · 2024: $37K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $119K · Travel and Lodging: $11K · Consulting Fee: $9,675 · Food and Beverage: $5,491 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $119,225.00 |
| Travel and Lodging | $10,884.88 |
| Consulting Fee | $9,675.00 |
| Food and Beverage | $5,490.92 |
| Education | $178.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $98,643.45 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $87,637.34 | 2019-2025 | Strensiq |
| Kyowa Kirin, INC. | $5,890.18 | 2024-2025 | Crysvita |
| Janssen Biotech, INC. | $246.87 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $197.48 | 2019-2024 | Orencia |
| Amgen INC. | $187.67 | 2020-2025 | Amjevita, Krystexxa, Evenity |
| Novartis Pharmaceuticals Corporation | $128.21 | 2019-2025 | |
| Genentech USA, INC. | $46.08 | 2019 | |
| Fujifilm Sonosite, INC. | $30.83 | 2021 | |
| Glaxosmithkline, LLC. | $21.04 | 2019 | |
| Horizon Therapeutics Plc | $20.39 | 2019 | |
| Mallinckrodt Enterprises LLC | $18.66 | 2019 | |
| Lilly USA, LLC | $16.51 | 2019 | |
| Pfizer INC. | $14.40 | 2019 | |
| Ferring Pharmaceuticals INC. | $12.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Reich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.